We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04456439
Previous Study | Return to List | Next Study

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04456439
Expanded Access Status : Available
First Posted : July 2, 2020
Last Update Posted : April 20, 2022
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast International Sàrl )

Study Description
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.

Condition or disease Intervention/treatment
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) Biological: Remestemcel-L Drug: Hydrocortisone Drug: Diphenhydramine

Detailed Description:
This intermediate-size expanded access protocol plans to treat approximately 50 children or adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2 months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the United States.
Study Design
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Resource links provided by the National Library of Medicine


Interventions
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Biological: Remestemcel-L
    Participants may receive up to 2 infusions of 2 x 10^6 remestemcel-L within a 5-day period.
  • Drug: Hydrocortisone
    Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
  • Drug: Diphenhydramine
    Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
    Other Name: Benadryl®
Eligibility Criteria
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 17 Years   (Child)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria

  1. 2 months to 17 years of age, inclusive
  2. Positive for current or recent SARS-CoV-2 (COVID-19) infection by real-time reverse transcription polymerase chain reaction (RT-PCR), serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms AND no alternative plausible diagnoses

  3. Presenting with:

    • Fever (>38.0°C or >100.4°F for ≥24 hours) or reporting subjective fever lasting ≥24 hours

    • Laboratory evidence of inflammation with high sensitivity C-reactive protein (hsCRP) ≥4.0 milligrams per deciliter (mg/dL) and associated abnormalities of at least one of the following:

      • elevated erythrocyte sedimentation rate (ESR)
      • elevated fibrinogen
      • elevated procalcitonin
      • elevated d-dimer
      • elevated ferritin
      • elevated lactic dehydrogenase (LDH)
      • elevated interleukin 6 (IL-6)
      • elevated neutrophils
      • reduced lymphocytes
      • low albumin

    • Clinically severe multisystem illness requiring hospitalization with evidence for cardiac involvement plus at least one other organ involvement (renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)

      • Cardiac involvement is defined as reduced left ventricular ejection fraction (<55%) in addition to at least one of the following:

        • increased troponin I,
        • increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) or BNP and/or
        • echocardiographic and/or other imaging evidence of left anterior descending coronary artery (LAD) and/or right coronary artery (RCA) dilation associated with a z-score > 2.5
  4. If on mechanical ventilation or ECMO, ≤72 hours post initiation of the respiratory support device

Exclusion Criteria

  1. Documented other microbial cause for MIS-C including bacterial sepsis, staphylococcal or streptococcal shock syndromes, or infections associated with myocarditis such as enterovirus. Of importance, waiting for results of these investigations should not delay initiation of remestemcel-L therapy.
  2. Females who are pregnant or lactating
  3. Body mass index (BMI) ≥40 kilograms per square meter (kg/m^2)
  4. Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins
  5. Aspartate aminotransferase/alanine transaminase (AST/ALT) ≥5x upper limit of normal (ULN)
  6. Creatinine clearance <30 mL/min
  7. Serum creatinine >2 mg/dL
  8. Any end-stage organ disease which in the opinion of the treating physician may possibly affect the safety of the remestemcel-L treatment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04456439


Contacts
Layout table for location contacts
Contact: Elizabeth Burke, ANP-C 646-315-1725 elizabeth.burke@mesoblast.com
Contact: Kenneth M. Borow, MD 610-299-7855 ken.borow@mesoblast.com

Sponsors and Collaborators
Mesoblast International Sàrl
Investigators
Layout table for investigator information
Study Director: Kenneth M. Borow, MD Mesoblast, Inc.
More Information
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Mesoblast International Sàrl
ClinicalTrials.gov Identifier: NCT04456439    
Other Study ID Numbers: MSB-MSC-MISC001
First Posted: July 2, 2020    Key Record Dates
Last Update Posted: April 20, 2022
Last Verified: April 2022
Keywords provided by Mesoblast, Ltd. ( Mesoblast International Sàrl ):
MIS-C
COVID-19
MSC
remestemcel-L
 Mesoblast
mesenchymal
cellular therapy
cells
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Coronavirus Infections
Syndrome
Disease
Pathologic Processes
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
 Diphenhydramine
Promethazine
Remestemcel-l
Hydrocortisone
Anti-Inflammatory Agents
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Sensory System Agents
Peripheral Nervous System Agents
Antiemetics
Autonomic Agents